Collagen-building skin peptide (Tripeptide-29 / Gly-Pro-Hyp)
A tiny protein fragment found in collagen that may help skin cells produce more collagen; used in cosmetic creams and oral collagen supplements, not an approved drug.
- Class
- Cosmetic peptide / collagen fragment
- Status
- Cosmetic INCI ingredient (topical); dietary supplement component (oral collagen hydrolysates); no drug approval
- Best-supported effect
- Collagen and ECM gene upregulation in cultured dermal fibroblasts (in vitro); measurable plasma bioavailability after oral collagen hydrolysate ingestion (human pharmacokinetic data)
- Main caveat
- No independent human RCT specifically tests isolated topical Tripeptide-29 on objective skin endpoints; oral collagen peptide RCTs test complex mixtures, not isolated GPH
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Cosmetic peptide / collagen fragment
Evidence tier: In vitro / assay evidence
Status: Cosmetic INCI ingredient (topical); dietary supplement component (oral collagen hydrolysates); no drug approval
Best-supported effect: Collagen and ECM gene upregulation in cultured dermal fibroblasts (in vitro); measurable plasma bioavailability after oral collagen hydrolysate ingestion (human pharmacokinetic data)
Main caveat: No independent human RCT specifically tests isolated topical Tripeptide-29 on objective skin endpoints; oral collagen peptide RCTs test complex mixtures, not isolated GPH
What this is
Tripeptide-29 is the cosmetic INCI designation for glycyl-prolyl-hydroxyproline (Gly-Pro-Hyp, abbreviated GPH) — a three-amino-acid fragment that is the most abundant repeating motif in the (Gly-X-Y)n triple helix of type I collagen. Because it reflects the dominant structural unit of collagen itself, it has been positioned as a "collagen-mimetic" signal peptide in topical cosmetic formulations.
This card covers two distinct contexts for the same tripeptide sequence, which carry very different evidence bases. The first is the cosmetic INCI ingredient: Tripeptide-29 is included in topical serums and creams, where the mechanistic case rests primarily on in vitro fibroblast work. The second is GPH as an oral digestion product: the same tripeptide is released during hydrolysis of dietary collagen and appears measurably in human plasma after collagen peptide supplementation — a pharmacokinetic finding that underpins oral collagen product claims. The oral collagen supplement evidence does not directly validate topical Tripeptide-29 as a cosmetic ingredient; those human trials test complex mixtures in which GPH is one of many bioactive fragments.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Not present for isolated Tripeptide-29 | No independent human RCT specifically testing topical Tripeptide-29 identified; human pharmacokinetic data shows plasma bioavailability after oral collagen hydrolysate ingestion, but this reflects mixture exposure, not isolated GPH efficacy |
| Animal | Weak | Animal models of oral collagen peptide supplementation show skin and cartilage improvements, but these test complex mixtures rather than isolated Tripeptide-29 |
| In vitro | Moderate | Collagen-derived peptides including GPH upregulate collagen and ECM gene expression, fibroblast proliferation, and hyaluronic acid production in cultured dermal fibroblasts |
| Computational | None identified | No docking, structure prediction, or computational modeling data identified |
| Mechanism | Plausible | Biological rationale as a matrix-mimetic or matrikine signal is coherent; specific receptor or signaling cascade for GPH less characterized than for better-studied cosmetic peptides |
The human trial evidence base for oral collagen peptide products (multiple placebo-controlled RCTs and meta-analyses) is not directly applicable here: those trials enrolled participants using collagen hydrolysate mixtures containing GPH alongside Pro-Hyp, Hyp-Gly, and other fragments. They are cited as supporting context for the oral bioavailability framing but must not be treated as evidence that the isolated topical INCI ingredient produces equivalent clinical effects.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Upregulates collagen and ECM gene expression in cultured fibroblasts | Supported (in vitro) | In vitro | Medium — cell assay findings; physiological relevance to topical use not established |
| GPH reaches human plasma intact after oral collagen hydrolysate ingestion | Supported (human pharmacokinetic) | Human | Medium — pharmacokinetic finding in oral context; does not validate topical efficacy |
| Topical Tripeptide-29 improves skin elasticity, hydration, or wrinkle depth | Not established | In vitro | Low — no independent human RCT testing the isolated topical ingredient identified |
| Oral collagen peptide supplements improve skin and joint outcomes | Supported (oral mixture RCTs) | Human | Medium — evidence is for complex collagen hydrolysate mixtures, not isolated Tripeptide-29; GPH contribution not individually determined |
| Topical Tripeptide-29 penetrates skin to reach viable dermal fibroblasts | Not established | In vitro | Low — skin penetration depth and delivered concentration to fibroblasts not established in attached sources |
Assay conditions
This section reports concentrations or conditions used in assays. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro assay | Cultured human dermal fibroblasts | Collagen-derived peptides including GPH at study-reported concentrations | Study-reported timepoints | Collagen gene expression, ECM gene upregulation, fibroblast proliferation, hyaluronic acid production | Not an in vivo exposure model; physiological relevance to topical skin delivery not established |
| Human pharmacokinetic study | Healthy adults (oral ingestion) | Oral collagen hydrolysate at study-reported dose | Plasma sampling at 1–2 hours post-ingestion | GPH plasma concentration (nanomolar-to-low-micromolar range) | Mixture exposure; GPH is one of many peptide fragments; does not establish topical efficacy |
Assay limitations
- In vitro fibroblast evidence for GPH does not establish topical clinical efficacy. Whether GPH delivered topically reaches dermal fibroblasts at physiologically relevant concentrations is not established in the available literature.
- Skin surface peptidases may hydrolyze the unmodified tripeptide before it penetrates viable epidermis; this is an open question unresolved in available data.
- The specific receptor or signaling cascade through which GPH acts in fibroblasts is not well characterized. Whether the observed gene expression changes reflect a dedicated receptor interaction, a ligand-mediated matrikine signal, or a generic amino acid availability effect remains unclear.
- Human plasma bioavailability data (oral ingestion) does not apply to topical administration.
- No human safety data specifically for isolated topical Tripeptide-29 is identified. Tolerability inference relies on the fact that Gly-Pro-Hyp is an endogenous collagen digestion product.
Regulatory status
No drug approval identified for Tripeptide-29. The compound operates under two distinct regulatory frameworks:
| Region / body | Status | Notes |
|---|---|---|
| US (topical) | Cosmetic ingredient | Regulated under FDA cosmetic law as an INCI-designated ingredient; not approved as a drug |
| US (oral) | Dietary supplement component | Oral collagen hydrolysate products regulated as dietary supplements, not drugs |
| EU (topical) | Cosmetic ingredient | Listed in EU cosmetic ingredient framework; not an approved drug |
| WADA | Not checked in this card | No anti-doping restriction identified in attached sources; status not independently verified |
per available sources safety note: Allergy to fish, bovine, or porcine source material may apply to oral collagen peptide products; topical cosmetic formulations derived from the same source materials may carry a similar sensitization risk. Injection is not an established route; cosmetic topical formulations are not sterile injectable products, and no published safety or rationale basis for injection is described in the available literature.
Mechanism
Tripeptide-29 (Gly-Pro-Hyp) is the most abundant repeating tripeptide in the type I collagen triple helix, where the (Gly-X-Y)n structure requires glycine at every third position and most commonly features proline at X and 4-hydroxyproline at Y. Two proposed mechanistic frames are described in the available literature.
Matrix-mimetic / matrikine framing (topical context): Collagen-derived fragments released during extracellular matrix turnover have been proposed to act as matrikines — signals to fibroblasts that matrix remodeling is underway. In vitro studies with collagen-derived peptides including GPH show upregulation of collagen gene expression, fibroblast proliferation, and hyaluronic acid production in cultured dermal fibroblasts. The specific receptor or signaling cascade mediating GPH's effects is less well characterized than the mechanisms proposed for other cosmetic peptides. Whether the in vitro activity reflects a dedicated receptor, a ligand-mediated signal, or a generic amino acid availability effect is an open question.
Oral bioavailability framing (oral supplement context): Unlike most peptides, which are rapidly hydrolyzed in the gastrointestinal tract, GPH and related collagen-derived di- and tripeptides (notably Pro-Hyp and Hyp-Gly) partially resist digestion and appear measurably in human plasma after oral collagen hydrolysate ingestion. Plasma GPH peaks within approximately 1–2 hours of ingestion at nanomolar-to-low-micromolar concentrations. Transport via PEPT1 (the proton-coupled oligopeptide transporter) is proposed in the available literature. This oral bioavailability finding provides a plausible systemic signaling story for the oral collagen peptide category but does not apply to topical administration.
Chemistry
| Field | Value |
|---|---|
| Common name | Tripeptide-29; Gly-Pro-Hyp; GPH |
| Systematic name | Glycyl-L-prolyl-L-hydroxyproline; Glycyl-L-prolyl-trans-4-hydroxy-L-proline |
| Amino acid chain | Gly-Pro-Hyp |
| Length | 3 amino acids |
| Topology | Linear |
| Modification | Contains 4-hydroxyproline (Hyp) — a post-translational modification characteristic of collagen; not encoded directly in DNA |
| Source note | Most abundant repeating tripeptide motif in type I collagen triple helix |
| Sequence confidence | Verified (canonical collagen repeat; endogenous collagen digestion product) |
Open questions
- Topical skin penetration: Whether unmodified Tripeptide-29 survives surface peptidases and reaches viable dermal fibroblasts at concentrations sufficient to exert the in vitro effects is not established. This is the central unresolved question for topical efficacy.
- Isolated-ingredient human RCT: No independent randomized trial specifically testing isolated topical Tripeptide-29 on objective skin endpoints (elasticity, hydration, wrinkle depth) is identified in the available literature. Such a trial would be needed to distinguish GPH's contribution from other formulation actives.
- Receptor characterization: The specific receptor or signaling pathway through which GPH activates fibroblast gene expression has not been identified in the available literature. This limits mechanistic confidence.
- Mixture attribution: In oral collagen hydrolysate RCTs, how much of the observed benefit is specifically attributable to GPH versus other bioactive fragments such as Pro-Hyp and Hyp-Gly has not been determined.
- Topical vs oral evidence boundary: The extent to which oral collagen supplement RCT evidence can inform predictions about topical cosmetic formulation performance remains formally unresolved.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could GPH work not by directly telling skin cells to make collagen, but by releasing a building block that mimics the chemical signal that low oxygen sends to those cells?
If true, this would explain why oral collagen supplements improve skin and would reveal that the active signal is not the peptide itself but a breakdown product, potentially allowing much smaller, cheaper doses to achieve the same benefit by targeting the real pathway directly.
Does removing just one hydroxyl group from GPH, creating the version often used in cheaper supplements, completely eliminate the peptide's ability to activate the cells that build collagen?
Billions of dollars are spent annually on collagen supplements. If the hydroxylated form is required for biological activity and cheaper non-hydroxylated versions are inactive, this would fundamentally change how collagen supplements are regulated, manufactured, and communicated to consumers.
Could GPH work in joints not by telling cells to make more collagen, but by physically getting in the way of the enzymes that break collagen down?
Osteoarthritis affects hundreds of millions of people and there is no drug that slows the actual joint damage. If collagen supplementation works by blocking the enzymes that destroy cartilage, that would give a simple, low-cost treatment a clear biological rationale and could lead to more potent versions that genuinely modify the course of the disease.
▸3-letter notation
▸citationbibtex
@peptide{pep10964,
sequence = {GPH},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}